Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to [...]